



PRESS RELEASE

Proteome Sciences plc
("Company" or the "Group")

AGM Statement and Result of AGM

24 June 2016

At the AGM held earlier today it was announced that revenues from the core biomarker services activities remained buoyant in the first half with a strong order book, including repeat business, and a developing pipeline. TMT revenue growth has continued into 2016 and TMT was highly visible at the recent meeting of the American Society for Mass Spectrometry. The growing recognition of tau as a therapeutic target in Alzheimer's disease should increase interest in new treatments which could favourably affect our compounds targeting CK1d in the tau pathway. We are confident that the business remains on track in 2016 to deliver a significant increase in revenues.

At the AGM all resolutions were duly passed.

– Ends –

For further information please contact:

Proteome Sciences plc

Dr. Jeremy Haigh, Chief Executive Officer

Dr. Ian Pike, Chief Operating Officer

Geoff Ellis, Finance Director

Tel: +44 (0)1932 865065

finnCap Limited (Nominated Adviser/Broker)

Geoff Nash/James Thompson

Tel : +44 (0)20 7220 0500

Public Relations

IKON Associates

Adrian Shaw

Email: adrian@ikonassociates.com

Tel: +44 (0)1483 271291

Mobile +44(0)7979 900733

Notes for editors:

About Proteome Sciences plc (www.proteomics.com)

With its HQ in Cobham, UK and laboratory facilities in London and Frankfurt, Proteome Sciences is a global leader in applied proteomics offering high sensitivity, proprietary technologies and workflows in cell signalling pathways (SysQuant[®], TMTcalibrator[™]) and in protein biomarker discovery, validation and assay development.

PS Biomarker Services[®] provides proteomics outsourcing services and proprietary biomarker assays from its ISO 9001: 2008 facility in Frankfurt, Germany to pharmaceutical, biotechnology, diagnostics companies and academia.

Proteome Sciences' research has discovered a large number of novel protein biomarkers in key human diseases with a focus mainly in neurological/neurodegenerative conditions and in cancer. It has patented blood biomarkers in Alzheimer's disease, stroke, brain damage and cancers for diagnostic and treatment applications that are available for licenses.